Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS |
| |
| Authors: | PA Calabresi NS Fields HW Maloni A Hanham J Carlino J Moore MC Levin S Dhib-Jalbut LR Tranquill H Austin HF McFarland MK Racke |
| |
| Affiliation: | Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1400, USA. |
| |
| Abstract: | Transforming growth factor (TGF)-beta2 is a pleiotropic cytokine associated with remissions in multiple sclerosis (MS) and amelioration of allergic encephalomyelitis. We assessed the safety of TGF-beta2 in an open-label trial of 11 patients with secondary progressive (SP) MS. Five patients had a reversible decline in the glomerular filtration rate. There was no change in expanded disability status scale or MRI lesions during treatment. Systemic TGF-beta2 may be associated with reversible nephrotoxicity, and further investigation of its therapeutic potential in MS should be performed with caution. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
